Talal Hilal, MB, BCh, assistant professor of Medicine at Mayo Clinic, discusses the benefit of maintenance rituximab (Rituxan) in the treatment of patients with mantle cell lymphoma (MCL).
Talal Hilal, MB, BCh
Advertisement
Articles by Talal Hilal, MB, BCh
Talal Hilal, MB, BCh, assistant professor of medicine, Mayo Clinic, discusses a study of rituximab (Rituxan) maintenance in patients with mantle cell lymphoma (MCL) after induction chemoimmunotherapy.
Talal Hilal, MB, BCh, assistant professor of medicine, Mayo Clinic, discusses the meta-analysis of rituximab maintenance for patients with mantle cell lymphoma.
Advertisement
Latest Updated Articles
Dr. Hilal Discusses Rituximab Maintenance in Mantle Cell LymphomaPublished: June 8th 2018 | Updated:
Dr. Hilal Discusses Study of Rituximab Maintenance in MCLPublished: July 13th 2018 | Updated:
Dr. Hilal on the Benefit of Maintenance Rituximab in Patients With MCLPublished: February 5th 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5